PE20151438A1 - Moduladores de receptores nmda de espiro-lactama y sus usos - Google Patents

Moduladores de receptores nmda de espiro-lactama y sus usos

Info

Publication number
PE20151438A1
PE20151438A1 PE2015001565A PE2015001565A PE20151438A1 PE 20151438 A1 PE20151438 A1 PE 20151438A1 PE 2015001565 A PE2015001565 A PE 2015001565A PE 2015001565 A PE2015001565 A PE 2015001565A PE 20151438 A1 PE20151438 A1 PE 20151438A1
Authority
PE
Peru
Prior art keywords
lactama
spiro
compounds
receiver modulators
nmda
Prior art date
Application number
PE2015001565A
Other languages
English (en)
Spanish (es)
Inventor
Lowe John A Iii
M Amin Khan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50097881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of PE20151438A1 publication Critical patent/PE20151438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2015001565A 2013-01-29 2014-01-29 Moduladores de receptores nmda de espiro-lactama y sus usos PE20151438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361757939P 2013-01-29 2013-01-29

Publications (1)

Publication Number Publication Date
PE20151438A1 true PE20151438A1 (es) 2015-10-10

Family

ID=50097881

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001565A PE20151438A1 (es) 2013-01-29 2014-01-29 Moduladores de receptores nmda de espiro-lactama y sus usos

Country Status (16)

Country Link
US (2) US9738650B2 (OSRAM)
EP (1) EP2951186B1 (OSRAM)
JP (1) JP2016506961A (OSRAM)
KR (1) KR20150110586A (OSRAM)
CN (1) CN105026401A (OSRAM)
AU (1) AU2014212490A1 (OSRAM)
BR (1) BR112015018095A2 (OSRAM)
CA (1) CA2899010A1 (OSRAM)
CL (1) CL2015002124A1 (OSRAM)
EA (1) EA201591404A1 (OSRAM)
IL (1) IL240165A0 (OSRAM)
MX (1) MX2015009778A (OSRAM)
PE (1) PE20151438A1 (OSRAM)
PH (1) PH12015501600A1 (OSRAM)
SG (1) SG11201505937SA (OSRAM)
WO (1) WO2014120789A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
ES2618421T3 (es) 2013-01-29 2017-06-21 Aptinyx Inc. Moduladores espiro-lactama del receptor NMDA y usos de los mismos
AU2014212487C1 (en) * 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2014120783A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112015018095A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CN105408336B (zh) 2013-01-29 2018-06-26 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
AU2017267708B2 (en) 2016-05-19 2020-02-20 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
ES2972533T3 (es) 2016-08-01 2024-06-13 Tenacia Biotechnology Hong Kong Co Ltd Moduladores del receptor de NMDA a base de espirolactama, y sus usos
AU2017306158B2 (en) * 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
ES2973283T3 (es) * 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de receptores de NMDA espirolactámicos y usos de los mismos
KR102761196B1 (ko) 2018-01-31 2025-02-03 테나시아 바이오테크놀로지 (홍콩) 코., 리미티드 스피로-락탐 nmda 수용체 조정제 및 그의 용도
SG11202007251XA (en) * 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152685A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and methods of using same
CN109485598A (zh) * 2018-11-29 2019-03-19 河南师范大学 一种去除氨基上喹啉保护基的新方法
MA56551A (fr) * 2019-06-24 2022-04-27 Naurex Inc Procédés et intermédiaires pour la production de composés de diazaspiro-lactame
CN114599354A (zh) * 2019-08-01 2022-06-07 阿普廷伊克斯股份有限公司 与nmda受体相互作用的抗体的水平升高相关性障碍的治疗方法
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
NZ332347A (en) 1996-06-07 2000-05-26 Zeneca Ltd Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues
WO1998005782A1 (en) 1996-08-02 1998-02-12 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
WO1999024584A1 (en) 1997-11-12 1999-05-20 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
US6521414B2 (en) 2000-02-01 2003-02-18 Agy Therapeutics, Inc. Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
WO2001098367A2 (en) 2000-06-22 2001-12-27 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US20020142287A1 (en) 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
AU2002248553A1 (en) 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
WO2002072609A2 (en) 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
WO2004005293A2 (en) 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2534909A1 (en) 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
RS52471B (sr) 2005-03-24 2013-02-28 Emory University Režimi doziranja za lečenje traumatske povrede mozga progesteronom
AU2006282942B2 (en) 2005-08-26 2012-07-26 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
JP2010503677A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝の障害を治療するためのアゼチジノン誘導体
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
US9783851B2 (en) 2008-02-20 2017-10-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
AU2009278075B2 (en) 2008-08-07 2013-07-04 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
EP2331571B1 (en) * 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
HRP20140784T1 (hr) 2009-10-05 2014-10-10 Northwestern University Glyx-13 za uporabu u postupku tretiranja refraktornih depresija
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
RU2566821C2 (ru) 2010-02-11 2015-10-27 Нортвестерн Юниверсити Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
BR112013027554A2 (pt) 2011-04-27 2016-09-06 Univ Northwestern "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
JP6388536B2 (ja) 2011-06-27 2018-09-12 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 超音波振動子アセンブリ及びその製造方法
BR112015018095A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CN105408336B (zh) 2013-01-29 2018-06-26 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
ES2618421T3 (es) 2013-01-29 2017-06-21 Aptinyx Inc. Moduladores espiro-lactama del receptor NMDA y usos de los mismos
WO2014120783A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212487C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof

Also Published As

Publication number Publication date
US20180155354A1 (en) 2018-06-07
IL240165A0 (en) 2015-09-24
CN105026401A (zh) 2015-11-04
SG11201505937SA (en) 2015-09-29
WO2014120789A1 (en) 2014-08-07
AU2014212490A1 (en) 2015-07-30
PH12015501600A1 (en) 2015-10-19
US9738650B2 (en) 2017-08-22
EP2951186A1 (en) 2015-12-09
JP2016506961A (ja) 2016-03-07
US10253032B2 (en) 2019-04-09
MX2015009778A (es) 2016-02-09
BR112015018095A2 (pt) 2017-07-18
KR20150110586A (ko) 2015-10-02
CL2015002124A1 (es) 2015-12-04
EP2951186B1 (en) 2018-07-25
EA201591404A1 (ru) 2016-01-29
CA2899010A1 (en) 2014-08-07
US20150376195A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151436A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
GT201400079A (es) Derivados de (4-fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX395013B (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos
GEP20207102B (en) Sulfonamides as modulators of sodium channels
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
MX2020008107A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.
MX2021000029A (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.

Legal Events

Date Code Title Description
FD Application declared void or lapsed